Publications by authors named "A Perfetti"
Article Synopsis
- The CheckMate-743 trial showed that nivolumab plus ipilimumab improves overall survival in patients with unresectable pleural mesothelioma compared to chemotherapy, but lacked representation of Latin American patients.
- A retrospective study evaluated this treatment's effectiveness and safety in 96 LATAM patients, focusing on their demographic and clinical characteristics, with a median follow-up of 24.1 months.
- Results indicated median progression-free survival of 8 months and overall survival of 22 months, confirming treatment benefits similar to other findings, with manageable adverse events reported.
Background: Programmed death ligand-1 (PD-L1) expression is a well-known predictive biomarker of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC). However, there is limited evidence of the relationship between PD-L1 expression, clinicopathological features, and their association with major driver mutations in NSCLC patients in Latin America.
Methods: This retrospective study included patients from Argentina with advanced NSCLC, and centralized evaluation of PD-L1 expression concurrently with genomic alterations in the driver genes EGFR, ALK, ROS1, BRAF, and/or KRAS G12C in FFPE tissue samples.
Purpose: Despite marked advances in the treatment of unresectable or metastatic melanoma, the need for novel therapies remains. Bempegaldesleukin (BEMPEG), a pegylated interleukin-2 (IL-2) cytokine prodrug, demonstrated efficacy in the phase II PIVOT-02 trial. PIVOT IO 001 (ClinicalTrials.
View Article and Find Full Text PDFThis study presents the landscape of private community sport organizations in the City of London, Ontario, Canada based on a profile of organizational features that align conceptually with critical aspects of community development. Features representing the scope-variety of sports offered, program age targets, and other offerings-and operations-nonprofit/commercial sector, open/closed program type, independent/affiliated/franchise status, and shared/exclusive facility use-of community sport organizations were captured from publicly available information about the population of 218 organizations. The location of sport delivery points for each organization was also mapped.
View Article and Find Full Text PDFArticle Synopsis
- CRISPR/Cas9 is a cutting-edge gene-editing technology showing potential for treating incurable genetic diseases like myotonic dystrophy.
- Recent experiments in models of myotonic dystrophy type 1 (DM1) have successfully targeted and removed harmful CTG-repeat expansions, leading to improvements in disease symptoms.
- The researchers developed a strategy using specific promoters to control gene editing in selected cells, ensuring effective gene therapy while minimizing unintended changes to other parts of the genome.